- Trials with a EudraCT protocol (251)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
251 result(s) found for: Anxiety disorders and symptoms.
Displaying page 1 of 13.
| EudraCT Number: 2006-005674-47 | Sponsor Protocol Number: CL3-20098-050 | Start Date*: 2007-10-26 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ... | |||||||||||||
| Medical condition: Generalised anxiety disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-001666-15 | Sponsor Protocol Number: CL3-20098-087 | Start Date*: 2013-06-11 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo given orally for 12 weeks in non depressed out-patients with Generalized Anxiety Disorder. A 12-week randomise... | |||||||||||||
| Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) SK (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-001779-35 | Sponsor Protocol Number: 4 | Start Date*: 2013-02-15 | |||||||||||
| Sponsor Name:University of Southampton | |||||||||||||
| Full Title: The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder | |||||||||||||
| Medical condition: Generalised anxiety disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003042-47 | Sponsor Protocol Number: InsulaTOP | Start Date*: 2015-12-16 | |||||||||||
| Sponsor Name:Centre Hospitalier Henri Laborit | |||||||||||||
| Full Title: Psycho-biological substrates of therapeutic benefit of thermal cure on Generalized Anxiety Disorders | |||||||||||||
| Medical condition: Generalised Anxiety Disorders | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-010902-13 | Sponsor Protocol Number: F1J-MC-HMGF(a) | Start Date*: 2010-08-03 | |||||||||||
| Sponsor Name:LILLY S.A. | |||||||||||||
| Full Title: Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anx... | |||||||||||||
| Medical condition: Trastorno de ansiedad generalizada Generalized anxiety disorder (GAD) | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DE (Completed) GB (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003659-19 | Sponsor Protocol Number: R317573DEP2002 | Start Date*: 2006-09-14 | |||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
| Full Title: A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiet... | |||||||||||||
| Medical condition: Anxiety disorders and depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004768-32 | Sponsor Protocol Number: A0081147 | Start Date*: 2008-04-21 | |||||||||||
| Sponsor Name:Pfizer S.A. | |||||||||||||
| Full Title: “ESTUDIO DE SEGURIDAD Y EFICACIA A LARGO PLAZO DE PREGABALINA EN SUJETOS CON TRASTORNO DE ANSIEDAD GENERALIZADA” "LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANX... | |||||||||||||
| Medical condition: Trastorno de ansiedad generalizada (TAG) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) LT (Completed) FI (Completed) AT (Completed) CZ (Completed) SI (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002263-17 | Sponsor Protocol Number: BRN-C-2017-01 | Start Date*: 2017-11-02 | |||||||||||
| Sponsor Name:BOIRON | |||||||||||||
| Full Title: Efficacy and safety of Passiflora Compose in patients newly diagnosed with adjustment disorder with anxiety, as first-line treatment, compared to alprazolam | |||||||||||||
| Medical condition: Adjustment disorder with anxiety | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004475-23 | Sponsor Protocol Number: 47410 | Start Date*: 2016-10-05 | |||||||||||
| Sponsor Name:Radboud University Nijmegen | |||||||||||||
| Full Title: Enhancement of exposure therapy for social anxiety disorder with testosterone: A randomized clinical trial | |||||||||||||
| Medical condition: Social Anxiety Disorder (Social Phobia) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005597-67 | Sponsor Protocol Number: EFC4846 | Start Date*: 2006-03-29 | |||||||||||
| Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
| Full Title: An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Di... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003739-62 | Sponsor Protocol Number: 2021-74835 | Start Date*: 2021-06-23 |
| Sponsor Name:University Medical Center Utrecht | ||
| Full Title: BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms | ||
| Medical condition: PTSD and anxiety disorders | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-013789-17 | Sponsor Protocol Number: CL3-20098-071 | Start Date*: 2010-03-11 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou... | |||||||||||||
| Medical condition: Generalized anxiety disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) CZ (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001599-46 | Sponsor Protocol Number: F1J-MC-HMGI | Start Date*: 2017-05-09 |
| Sponsor Name:Eli Lilly and Company Limited | ||
| Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | ||
| Medical condition: Generalized Anxiety Disorder | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2008-000971-15 | Sponsor Protocol Number: P1V-ANX-CT01-07 | Start Date*: 2008-07-02 | |||||||||||
| Sponsor Name:University of Bristol | |||||||||||||
| Full Title: Evaluation of the effects of chronic treatment with venlafaxine (150 mg) and pregabalin (200 mg) on emotional indices of anxiety and panic induced by breathing carbon dioxide. | |||||||||||||
| Medical condition: Generalised anxiety disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-004006-81 | Sponsor Protocol Number: LTE5376 | Start Date*: 2006-06-01 | |||||||||||
| Sponsor Name:sanofi-aventis recherche&developpement | |||||||||||||
| Full Title: A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of d... | |||||||||||||
| Medical condition: patients with major depressive disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) FI (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004077-16 | Sponsor Protocol Number: 14/0249 | Start Date*: 2014-12-03 | |||||||||||
| Sponsor Name:University College London Joint Research Office | |||||||||||||
| Full Title: A Phase IV randomised controlled trial of the selective serotonin reuptake inhibitor Sertraline versus Cognitive Behavioural Therapy for anxiety symptoms in people with Generalised Anxiety Disorder... | |||||||||||||
| Medical condition: Generalised anxiety disorder (GAD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-000761-32 | Sponsor Protocol Number: A5361018 | Start Date*: 2008-09-05 | |||||||||||
| Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G... | |||||||||||||
| Medical condition: Generalized Anxiety Disorder (GAD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005054-46 | Sponsor Protocol Number: D1448C00011 | Start Date*: 2006-03-17 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR... | ||
| Medical condition: Generalised Anxiety Disorder (GAD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) FI (Completed) ES (Completed) DK (Completed) DE (Completed) SK (Completed) CZ (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-019369-27 | Sponsor Protocol Number: ANX001-01 | Start Date*: 2010-07-23 | |||||||||||
| Sponsor Name:Anxiofit Ltd. | |||||||||||||
| Full Title: A Phase II randomized, double-blind, parallel-group, multi-site, placebo controlled fixed-dose study of Echinaceae angustifoliae root dry extract in 24 outpatients with generalized anxiety disorder... | |||||||||||||
| Medical condition: Generalized Anxiety Disorder (GAD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003699-37 | Sponsor Protocol Number: CL3-20098-089 | Start Date*: 2013-01-17 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in... | |||||||||||||
| Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) DE (Completed) HU (Completed) PL (Completed) FI (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.